Siddhanta Medicity to raise USD 108 Million in partnership with UK-based SRAM & MRAM Group

New Delhi: Siddhanta Medicity, an esteemed healthcare institution based in India, has recently entered into a ground-breaking collaboration with the UK-based SRAM & MRAM Group.

With this collaboration, Siddhanta Medicity is set to raise a significant investment of USD 108 Million in partnership. This collaborative effort aims to advance the realms of clinical research and development in the field of NK Cell and Mesenchymal Stem Cell Therapies.

The partnership signifies a pivotal step forward in the pursuit of innovative medical solutions. By combining the expertise and resources of these two esteemed entities, the collaboration seeks to push the boundaries of medical science and improve patient outcomes. Through this investment, Siddhanta Medicity is poised to establish a network of hospitals across India.

NK Cell therapy, a cutting-edge approach in cancer treatment, harnesses the power of the body’s natural killer (NK) cells to target and destroy cancer cells. Mesenchymal Stem Cell therapy, on the other hand, holds immense promise in regenerative medicine, aiming to repair and regenerate damaged tissues and organs.

Through this collaboration, both companies aspire to conduct comprehensive clinical research, refining the understanding of NK Cell and Mesenchymal Stem Cell therapies. This will involve rigorous testing, analysis, and optimization of these therapies to ensure their safety and effectiveness for a wide range of medical conditions. The combined efforts of are poised to contribute significantly to the global healthcare landscape. By pushing the boundaries of medical research and development, this partnership holds the potential to bring about ground-breaking advancements that could revolutionize patient care and treatment outcomes.

This infusion of collaboration promises to invigorate and drive the expansion of the partnership, propelling rapid advancements in ground-breaking stem cell treatments and therapies. The SRAM & MRAM Group’s strategic entry into the Indian market, in conjunction with CELLAAX, a distinguished biopharmaceutical firm renowned for its pioneering cellular therapy research and development, is set to initiate its operations within India. The inaugural phase of this transformative venture will be characterized by a strategic partnership with the esteemed Siddhanta Hospital, located in Bhopal.

Speaking on the development, Dr. Subodh Varsheny, quoted, “The investment of USD 108 Million will play a pivotal role in establishing cutting-edge stem cell research centers, state-of-the-art treatment facilities, and advanced laboratories that will be equipped with the latest technologies. The collaborative effort aims to bring together leading scientists, researchers, and medical professionals to accelerate the development of novel stem cell therapies, tailored to address the specific healthcare needs of Indian patients.”, quoted.

“We are excited about the collaboration and the remarkable possibilities it presents, in advancing stem cell treatment in India. This investment reaffirms our commitment to driving progress in healthcare, and together, we aim to make regenerative medicine more accessible to patients across the country”, expressed, Dr. Sailesh Lachu Hiranandani, Chairman, SRAM & MRAM Group.

In addition to research and treatment centers, the collaboration will focus on extensive clinical trials to establish the safety and efficacy of stem cell therapies. These trials will adhere to the highest ethical and regulatory standards, paving the way for the acceptance and widespread adoption of stem cell treatments within the medical community.

Speaking on the India operations, Alex Wong, Founder & CEO of CELLAAX, shared her optimism about the collaboration, saying, “CELLAAX is dedicated to pushing the boundaries of stem cell research and clinical applications. With this collaboration in India, we’ll be able to propel our research endeavours and take significant strides in making stem cell treatments a reality for patients in India.”